This study will be restricted to all original articles of healthy adults (people not suffering from any diseases). However, we will also include grade I hypertensive people as an exception. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
Kagome Co., Ltd.
Review Team Professor Hiroharu Kamioka, Department of Ecological Symbiotic Science, Tokyo University of Agriculture Dr. Takahiro Yoshizaki, Department of Food and Nutritional Sciences, Toyo University Ms. Mari Makishi, Narashino Media Center, Toho University Mr. Takuro Inoue, Innovation Division, Kagome Co., Ltd. Ms. Erika Sasaki, Innovation Division, Kagome Co., Ltd. Dr. Nobuhiro Yajima, Innovation Division, Kagome Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized and quasi randomized and non-randomized controlled trials, randomized crossover trials, cohort studies, and case-control studies. We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include people not suffering from any diseases and also include grade I hypertensive people as an exception. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Intervention: We define oral intake of test food containing GABA as an intervention. Comparison: We define oral intake of test food not containing GABA or maintaining daily life as controls. Outcome measurement: We will evaluate systolic blood pressure and diastolic blood pressure. (PECO) Participant: We will include people not suffering from any diseases and also include grade I hypertensive people as an exception. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Exposure: We define oral intake of food containing GABA as an exposure. Comparison: We define eating no food containing GABA as non-exposure. If subgroup analysis of GABA intake amount has been conducted in a study, we define the least intake group as a non-exposure group. Outcome measurement: We will evaluate systolic blood pressure and diastolic blood pressure. (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude cross-sectional studies because it will be difficult to interpret causal relationships between exposure and outcome. We will also exclude proceedings and unpublished studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of oral intake of gamma-aminobutyric acid (GABA) on systolic blood pressure and diastolic blood pressure. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will not define the secondary outcomes. | — |
Countries
Japan
Contacts
Public ContactKoichi Aizawa
Kagome Co., Ltd. Innovation Division
Outcome results
None listed